VENN STRATEGIES

Lobbying for UCB, INC. · Biopharmaceutical company dealing in severe diseases in immunology and neurology.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Georgia · House · Senate · $80,000.00 income · posted Jul 17, 2026

Lobbying activity 2

Health Issues

Policies related to biopharmaceutical access and innovation.

Taxation/Internal Revenue Code

International tax issues and the corporate rate

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.